BACKGROUND Advanced oxidation protein products (AOPPs) are acknowledged as a novel marker of oxidation-mediated protein damage. This study aimed to investigate the plasma levels of AOPPs in postmenopausal osteoporotic @entity1 , and to determine the relationship between AOPPs accumulation and lumbar @entity79 ( @entity79 ) or bone turnover markers. MATERIAL AND METHODS Lumbar @entity79 was measured by dual-energy X-ray absorptiometry. Plasma AOPPs levels as a marker of protein oxidation damage and @entity1234 ( @entity1865 ) levels as a marker of lipid peroxidation were measured by spectrophotometry. The concentrations of 2 specific markers of bone turnover, bone-specific alkaline phosphatase (BALP) and @entity5272 -resistant acid phosphatase5b, (TRACP 5b) were quantified using ELISA kits. RESULTS We recruited 60 postmenopausal @entity1 meeting @entity170 ( @entity170 ) diagnostic criteria of World Health Organization (WHO) and 60 postmenopausal @entity1 without @entity170 . Plasma levels of AOPPs (P<0.001), BALP (P<0.001) and TRACP 5b (P<0.001) were statistically significantly increased in the postmenopausal osteoporotic @entity1 compared with controls, but there was no statistically significant difference in @entity1865 (P=0.124) between the 2 groups. Plasma AOPPs levels were negatively correlated with lumbar @entity79 and positively correlated with bone turnover markers both in postmenopausal osteoporotic @entity1 and in all subjects. However, plasma @entity1865 levels were not correlated with lumbar @entity79 or bone turnover markers. CONCLUSIONS In postmenopausal osteoporotic @entity1 elevated AOPPs is associated with reduced @entity79 and @entity79 markers. Because AOPPs is stable and easy to detect it may be used as a simple plasma marker to predict the severity of postmenopausal @entity170 .

Advanced Oxidation Protein Products as a Novel Marker of Oxidative Stress in XXXX .

@entity1 :: ('9606', 'Species') :: ['women'] @entity5272 :: ('MESH:C029768', 'Chemical') :: ['tartrate'] @entity170 :: ('MESH:D010024', 'Disease') :: ['OP', 'osteoporosis'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral destiny', 'BMD', 'increased bone turnover'] @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde'] @entity1865 :: ('CHEBI:566274', 'Chemical') :: ['MDA']
@entity170 :: (MESH:D010024,Disease) :: ['Postmenopausal Osteoporosis']
